HK1148533A1 - Prodrugs of piperazine and substituted piperidine antiviral agents - Google Patents

Prodrugs of piperazine and substituted piperidine antiviral agents

Info

Publication number
HK1148533A1
HK1148533A1 HK11102611.2A HK11102611A HK1148533A1 HK 1148533 A1 HK1148533 A1 HK 1148533A1 HK 11102611 A HK11102611 A HK 11102611A HK 1148533 A1 HK1148533 A1 HK 1148533A1
Authority
HK
Hong Kong
Prior art keywords
prodrugs
piperazine
antiviral agents
substituted piperidine
piperidine antiviral
Prior art date
Application number
HK11102611.2A
Other languages
English (en)
Inventor
Yasutsugu Ueda
Timothy P Connolly
John F Kadow
Nicholas A Meanwell
Tao Wang
Chung-Pin H Chen
Kap-Sun Yeung
Zhongxing Zhang
David Kenneth Leahy
Shawn K Pack
Nachimuthu Soundararajan
Pierre Sirard
Kathia Levesque
Dominique Thoraval
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1148533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1148533A1 publication Critical patent/HK1148533A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK11102611.2A 2004-03-15 2011-03-15 Prodrugs of piperazine and substituted piperidine antiviral agents HK1148533A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55332004P 2004-03-15 2004-03-15
US63523104P 2004-12-10 2004-12-10

Publications (1)

Publication Number Publication Date
HK1148533A1 true HK1148533A1 (en) 2011-09-09

Family

ID=34963934

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07104164A HK1096687A1 (en) 2004-03-15 2007-04-20 Prodrugs of piperazine and substituted piperidine antiviral agents
HK11102611.2A HK1148533A1 (en) 2004-03-15 2011-03-15 Prodrugs of piperazine and substituted piperidine antiviral agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07104164A HK1096687A1 (en) 2004-03-15 2007-04-20 Prodrugs of piperazine and substituted piperidine antiviral agents

Country Status (27)

Country Link
US (12) US7745625B2 (xx)
EP (1) EP1725569B1 (xx)
JP (1) JP4734318B2 (xx)
KR (1) KR101153594B1 (xx)
CN (1) CN101941990B (xx)
AR (1) AR048039A1 (xx)
AT (1) ATE384728T1 (xx)
AU (1) AU2005223736C1 (xx)
BR (1) BRPI0508876B8 (xx)
CA (1) CA2560253C (xx)
CY (1) CY1107419T1 (xx)
DE (1) DE602005004517T2 (xx)
DK (1) DK1725569T3 (xx)
ES (1) ES2299022T3 (xx)
GE (1) GEP20094736B (xx)
HK (2) HK1096687A1 (xx)
HR (1) HRP20080064T5 (xx)
IL (1) IL211961A (xx)
MY (1) MY139243A (xx)
NO (1) NO336742B1 (xx)
NZ (2) NZ549867A (xx)
PE (1) PE20051151A1 (xx)
PL (1) PL1725569T3 (xx)
PT (1) PT1725569E (xx)
RS (1) RS50567B (xx)
TW (1) TWI344843B (xx)
WO (1) WO2005090367A1 (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1678321A (zh) * 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US7122542B2 (en) * 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7130185B2 (en) * 2004-06-02 2006-10-31 Research In Motion Limited Handheld computing device having drop-resistant LCD display
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
DK1856135T3 (da) 2005-01-19 2010-04-12 Rigel Pharmaceuticals Inc Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7396830B2 (en) 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
US8242124B2 (en) * 2008-06-25 2012-08-14 Bristol-Myers Squibb Company Diketopiperidine derivatives as HIV attachment inhibitors
ES2462403T3 (es) * 2008-06-25 2014-05-22 Bristol-Myers Squibb Company Diceto azolopiperidinas y azolopiperazinas como agentes anti-VIH
SI2323633T1 (sl) * 2008-09-04 2012-07-31 Bristol Myers Squibb Co Stabilni farmacevtski sestavek za optimizirano razdeljevanje hiv pripetih inhibitorjev
CA2740017A1 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010151711A1 (en) * 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
WO2011056240A2 (en) * 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8802661B2 (en) 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
US8754068B2 (en) 2010-06-04 2014-06-17 Bristol-Myers Squibb Company Modified C-3 betulinic acid derivatives as HIV maturation inhibitors
EP2601174B1 (en) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
PT2670764E (pt) 2011-01-31 2015-11-20 Bristol Myers Squibb Co C-28 aminas de derivados de ácido betulínico c-3 modificado como inibidores de maturação de vih
HUE026880T2 (en) * 2011-01-31 2016-08-29 Bristol Myers Squibb Co Procedures for the preparation of HIV binding inhibitor prodrug compound and intermediate products
PT2670765T (pt) 2011-01-31 2018-01-08 Viiv Healthcare Uk No 4 Ltd Triterpenoides modificados em c-17 e c-3 com atividade inibidora da maturação do vih
ES2636312T3 (es) 2011-04-12 2017-10-05 VIIV Healthcare UK (No.5) Limited Derivados de tioamida, amidoxima y amidrazona como inhibidores de la fijación del VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
TW201317255A (zh) 2011-09-21 2013-05-01 必治妥美雅史谷比公司 具抗病毒活性之新穎樺木酸衍生物
EP2783219A1 (en) 2011-11-21 2014-10-01 Bristol-Myers Squibb Company Methods for determining the susceptibility of a virus to an attachment inhibitor
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
ES2644747T3 (es) 2012-02-08 2017-11-30 Viiv Healthcare Uk (No. 4) Limited Procedimientos de preparación de un compuesto de profármaco de piperazina inhibidor de la fijación del VIH
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
DK2861608T3 (da) 2012-06-19 2019-06-24 Debiopharm Int Sa Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
WO2014025854A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
AU2014215468B2 (en) 2013-02-06 2017-05-18 VIIV Healthcare UK (No.5) Limited C-19 modified triterpenoids with HIV maturation inhibitory activity
CA2902513A1 (en) 2013-02-25 2014-08-28 Bristol-Myers Squibb Company C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
CN105229006A (zh) * 2013-03-27 2016-01-06 百时美施贵宝公司 作为hiv吸附抑制剂的哌嗪和高哌嗪衍生物
WO2014160692A1 (en) * 2013-03-27 2014-10-02 Bristol-Myers Squibb Company 2-keto amide derivatives as hiv attachment inhibitors
CN106604909B (zh) 2014-04-11 2019-02-15 Viiv保健英国第四有限公司 具有hiv成熟抑制活性的在3位被带有卤代烷基取代基的非芳族环取代的三萜系化合物
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
CA2967684A1 (en) 2014-11-14 2016-05-19 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
EP3218387A1 (en) 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
BR112017012643A2 (pt) 2014-12-18 2018-01-09 Viiv Healthcare Uk No 4 Ltd processo para preparação de um composto, e, método para fabricação de um composto.
US20170362262A1 (en) 2014-12-18 2017-12-21 ViiV Healthcare UK (No.4) Limited A process for preparing halogenated azaindole compounds using pybrop
CA2981056A1 (en) 2015-04-14 2016-10-20 ViiV Healthcare UK (No.4) Limited Methods of producing an hiv maturation inhibitor
AU2016331065B2 (en) 2015-10-01 2021-04-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs
JP6898931B2 (ja) * 2015-12-14 2021-07-07 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ ３，５−ジフェニル−ジアゾール化合物の水溶性誘導体
EP3411033A1 (en) 2016-02-04 2018-12-12 ViiV Healthcare UK (No.5) Limited Fostemsavir for use in heavily treatment-experienced hiv-1 infected individuals
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN108778286A (zh) 2016-02-26 2018-11-09 德彪药业国际股份公司 用于治疗糖尿病足感染的药物
HUE061885T2 (hu) 2017-11-21 2023-08-28 Pfizer 4-(4-(4-(1-Izopropil-7-oxo-1,4,6,6,7-tetrahidrospiro[indazol-5,4'-piperidin] -1'-karbonil)-6-metoxipiridin-2-il)-benzoesav kristályos 2-amino-2-(hidroximetil)-propán-1,3-diol sója
US20220106341A1 (en) 2019-01-17 2022-04-07 Viiv Healthcare Uk (No. 4) Limited Process for preparing fostemsavir
IL313306A (en) 2021-12-17 2024-08-01 Viiv Healthcare Co Combined treatments for HIV infections and their uses
US20240166728A1 (en) 2022-11-02 2024-05-23 VIIV Healthcare UK (No.5) Limited Antigen binding proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2101017C (en) 1992-07-24 1999-10-26 Masahiko Higuma Ink jet cartridge, ink jet head and printer
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
ATE304853T1 (de) * 2000-07-10 2005-10-15 Bristol Myers Squibb Co Zusammensetzung und antivirale wirkung von substituierten indol-oxo-aceto-piperidin- derivaten
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PT1363705E (pt) * 2001-02-02 2012-08-17 Bristol Myers Squibb Co Composição e actividade antiviral de derivados de piperazina azaindoleoxoacética substituídos
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
AU2003215469A1 (en) 2002-03-28 2003-10-13 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7776863B2 (en) 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US7130185B2 (en) * 2004-06-02 2006-10-31 Research In Motion Limited Handheld computing device having drop-resistant LCD display
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
HUE026880T2 (en) * 2011-01-31 2016-08-29 Bristol Myers Squibb Co Procedures for the preparation of HIV binding inhibitor prodrug compound and intermediate products
ES2644747T3 (es) * 2012-02-08 2017-11-30 Viiv Healthcare Uk (No. 4) Limited Procedimientos de preparación de un compuesto de profármaco de piperazina inhibidor de la fijación del VIH

Also Published As

Publication number Publication date
HK1096687A1 (en) 2007-06-08
US20150315218A1 (en) 2015-11-05
WO2005090367A1 (en) 2005-09-29
RU2374256C2 (ru) 2009-11-27
US20160361328A1 (en) 2016-12-15
US20180000849A1 (en) 2018-01-04
NZ585294A (en) 2011-09-30
US20190111066A1 (en) 2019-04-18
NO20064062L (no) 2006-12-08
PE20051151A1 (es) 2006-01-20
IL211961A (en) 2013-08-29
TW200600096A (en) 2006-01-01
CN101941990A (zh) 2011-01-12
RU2006136390A (ru) 2008-04-27
AU2005223736B2 (en) 2011-05-26
US7745625B2 (en) 2010-06-29
RS50567B (sr) 2010-05-07
TWI344843B (en) 2011-07-11
PL1725569T3 (pl) 2008-09-30
AU2005223736C1 (en) 2011-10-06
US20150025240A1 (en) 2015-01-22
US20100210599A1 (en) 2010-08-19
DE602005004517T2 (de) 2009-01-22
US8461333B2 (en) 2013-06-11
JP4734318B2 (ja) 2011-07-27
NO336742B1 (no) 2015-10-26
CA2560253C (en) 2013-01-15
PT1725569E (pt) 2008-03-28
US20200046743A1 (en) 2020-02-13
DK1725569T3 (da) 2008-06-02
CN101941990B (zh) 2012-04-25
ATE384728T1 (de) 2008-02-15
BRPI0508876B8 (pt) 2021-05-25
US20120238755A1 (en) 2012-09-20
MY139243A (en) 2009-09-30
GEP20094736B (en) 2009-07-27
KR20060129533A (ko) 2006-12-15
BRPI0508876B1 (pt) 2020-05-26
EP1725569B1 (en) 2008-01-23
HRP20080064T3 (en) 2008-03-31
US20150232414A1 (en) 2015-08-20
EP1725569A1 (en) 2006-11-29
US20050209246A1 (en) 2005-09-22
US20130253196A1 (en) 2013-09-26
US8871771B2 (en) 2014-10-28
US11369624B2 (en) 2022-06-28
DE602005004517D1 (de) 2008-03-13
US8168615B2 (en) 2012-05-01
HRP20080064T5 (en) 2008-10-31
JP2007529519A (ja) 2007-10-25
NZ549867A (en) 2010-07-30
US20210023098A1 (en) 2021-01-28
BRPI0508876A (pt) 2007-09-04
AU2005223736A1 (en) 2005-09-29
KR101153594B1 (ko) 2012-07-05
ES2299022T3 (es) 2008-05-16
CA2560253A1 (en) 2005-09-29
CY1107419T1 (el) 2012-12-19
AR048039A1 (es) 2006-03-22

Similar Documents

Publication Publication Date Title
HK1148533A1 (en) Prodrugs of piperazine and substituted piperidine antiviral agents
IL194540A0 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
IL186804A0 (en) A combination of a pde4 inhibitor and a tetrahydrobiopterin derivative
PL1802579T3 (pl) Pochodne 3-aryloaminopirydynowe
ZA200800256B (en) Antiviral compounds and methods
PL1648874T3 (pl) Pochodne piperazyny i ich zastosowanie jako środków leczniczych
IL181433A0 (en) Pyrimidine derivatives
IL181609A0 (en) Combination comprising zd6474 and imatinib
IL183216A0 (en) Nepetalactams and n-substituted derivatives thereof
IL181386A0 (en) Pyrimidine derivatives
IL183657A0 (en) Amide derivatives
IL179914A0 (en) Pyrimidine derivatives
IL176922A0 (en) Compositions and methods of use of a-type procyanidins
IL188928A0 (en) Indol-3-yl-carbonyl-piperidin and piperazin derivatives
IL183293A0 (en) Malonamide derivatives
IL176426A0 (en) Di-steroidal prodrugs of estradiol
EP1737458A4 (en) R (-) - 11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF
IL183217A0 (en) Dihydronepetalactams and n-substituted derivatives thereof
GB0415367D0 (en) Pyrimidine derivatives
ZA200607466B (en) Prodrugs of piperazine and substituted piperidine antiviral agents
ZA200808819B (en) Diketo-piperazine and piperidine derivatives as antiviral agents
IL177945A0 (en) Prodrugs of piperazine and substituted piperidine antiviral agents
SI1725569T1 (sl) Predzdravila piperazinskih in substituiranih piperidinskih protivirusnih sredstev
ZA200702227B (en) Combination comprising ZD6474 and imatinib
ZA200705150B (en) Amide derivatives